Department of Psychiatry, University of Melbourne, Parkville, VIC, Australia.
J Affect Disord. 2013 Sep 5;150(2):344-9. doi: 10.1016/j.jad.2013.04.016. Epub 2013 May 14.
Mental illness has been observed to follow a neuroprogressive course, commencing with prodrome, then onset, recurrence and finally chronic illness. In bipolar disorder and schizophrenia responsiveness to treatment mirrors these stages of illness progression, with greater response to treatment in the earlier stages of illness and greater treatment resistance in chronic late stage illness. Using data from 5627 participants in 15 controlled trials of duloxetine, comparator arm (paroxetine, venlafaxine, escitalopram) or placebo for the treatment of an acute depressive episode, the relationship between treatment response and number of previous depressive episodes was determined. Data was dichotomised for comparisons between participants who had >3 previous episodes (n=1697) or ≤3 previous episodes (n=3930), and additionally for no previous episodes (n=1381) or at least one previous episode (n=4246). Analyses were conducted by study arm for each clinical trial, and results were then pooled. There was no significant difference between treatment response and number of previous depressive episodes. This unexpected finding suggests that treatments to reduce symptoms of depression during acute illness do not lose efficacy for patients with a longer history of illness.
精神疾病呈现神经进行性发展过程,起始于前驱期,然后是发病、复发,最终发展为慢性疾病。在双相情感障碍和精神分裂症中,对治疗的反应反映了疾病进展的这些阶段,在疾病的早期阶段治疗反应更大,而在慢性晚期疾病中治疗抵抗更大。使用来自 15 项对照试验的 5627 名参与者的数据,这些试验评估了度洛西汀与对照组(帕罗西汀、文拉法辛、艾司西酞普兰)或安慰剂治疗急性抑郁发作的疗效,研究人员确定了治疗反应与之前抑郁发作次数之间的关系。数据分为之前有>3 次发作的参与者(n=1697)或≤3 次发作的参与者(n=3930),以及无之前发作的参与者(n=1381)或至少有一次发作的参与者(n=4246)进行比较。对每个临床试验的研究组进行了分析,然后汇总结果。治疗反应与之前抑郁发作次数之间无显著差异。这一意外发现表明,在急性疾病期间减轻抑郁症状的治疗方法不会因患者疾病史较长而降低疗效。